Beta Thalassemia – Epidemiology – Mature markets
Clarivate Epidemiology’s coverage of beta thalassemia (BT) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of BT for each country, as well as annualized case counts projected to the national population.
Clarivate Epidemiology’s BT forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of BT?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of BT over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 30 BT patient populations, as follows:
- Diagnosed BT prevalent cases.
- Diagnosed BT major prevalent cases.
- Diagnosed BT intermedia prevalent cases.
- Diagnosed B0/B0 BT major prevalent cases.
- Diagnosed B0/B+ BT major prevalent cases.
- Diagnosed B+/B+ BT major prevalent cases.
- Diagnosed B0/B0 BT major prevalent cases with matched related HSC transplantation – younger than 12 years old.
- Diagnosed B0/B0 BT major prevalent cases with matched related HSC transplantation – 12 years of age or older.
- Diagnosed B0/B0 BT prevalent cases without matched related HSC transplantation – younger than 12 years old.
- Diagnosed B0/B0 BT prevalent cases without matched related HSC transplantation – 12 years of age or older.
- Diagnosed BT intermedia prevalent cases requiring transfusions.
- Diagnosed BT major pediatric prevalent cases.
- Diagnosed BT major adult prevalent cases.
- … and many more (details available on request).
Note: coverage may vary by country.
Table of contents
- Beta Thalassemia - Epidemiology - Mature markets
- Epidemiology Data
- Methods
- Literature review (studies included in/excluded from the analyses of beta thalassemia)
- Diagnosed prevalent cases
- Diagnosed prevalent cases of beta thalassemia by severity
- Diagnosed BT major prevalent cases by genotype
- Diagnosed BT major prevalent cases by status of matched HSC transplantation
- Diagnosed BT intermedia prevalent cases by transfusion requirement
- Drug-treated populations
- Risk/protective factors applied to disease forecast models
- Reference Materials
